Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in semi-synthetic penicillin's, Aurobindo Pharma has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Anti-biotics Through cost-effective manufacturing capabilities and a few loyal customers, the company also entered the high-margin specialty generic formulations segment. Today Aurobindo Pharma has evolved into a knowledge-driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries.
Read More